1/3/2024 0 Comments Lama laba for copd![]() ![]() “We look forward to launching in the US in the coming months alongside our aclidinium monotherapy, Tudorza, as part of the significant LAMA/LABA market that is predicted to grow rapidly over the coming years,” said Steve Harris, Circassia’s chief executive.Ĭircassia expects to launch Duaklir in the United States in the second half of 2019, the company said in a news release.Īccording to Medscape, aclidinium bromide and formoterol fumarate have already been individually approved for COPD in the United States and Europe, while the Duaklir combination was approved by the European Medicines Agency for COPD in 2014. 6 Among the causes of nonadherence is the inability to use an inhaler as directed. 5 Adherence to inhaled medication in patients with COPD is low, with the nonadherence rate ranging from 50 to 80. The 2021 update included information regarding the use of e-cigarettes as nicotine replacement, triple therapy, and how the SARS-CoV-2 virus impacted patients with COPD. For select patients with COPD, nebulized drugs might offer an alternative to a breath-actuated, hand-held inhaler. The label also includes clinical data from the phase IV ASCENT study, which shows aclidinium therapy is effective at reducing COPD exacerbations.Īccording to Circassia Pharma, Duaklir is the only twice-daily LAMA/LABA in the US with COPD exacerbation data included in its prescribing information. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines classify a patient’s COPD and provide recommendations for first-line treatment. However, it is still unclear whether LABA or LAMA should be used for the initial treatment. ![]() The approval is based on data from three phase III studies: ACLIFORM, AUGMENT and AMPLIFY. Inhaled bronchodilators including long-acting beta-agonist (LABA) and long-acting muscarinic antagonist (LAMA) play a central role in the treatment of stable chronic obstructive pulmonary disease (COPD). The US FDA has approved twice-daily Duaklir, a fixed-dose combination LAMA/LABA for the maintenance treatment of COPD, according to manufacturer Circassia Pharmaceuticals.ĭuaklir is a fixed-dose combination of the LAMA aclidinium bromide (400 mcg) and LABA formoterol fumarate (12 mcg) and is administered twice-daily via AstraZeneca’s Pressair breath-actuated inhaler. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |